Analysts at Guggenheim began coverage on shares of Dermira (NASDAQ:DERM) in a research note issued on Tuesday, MarketBeat reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Leerink Swann reissued an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 16th. Mizuho reissued a “buy” rating and set a $43.00 price target (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 price target (down from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Four equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $43.33.

Dermira (NASDAQ DERM) traded up $1.29 during trading on Tuesday, hitting $26.09. The stock had a trading volume of 658,110 shares, compared to its average volume of 577,369. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. Dermira has a 12 month low of $21.35 and a 12 month high of $38.75.

In other Dermira news, CEO Thomas G. Wiggans sold 9,500 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of the stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,800 shares of company stock worth $809,425. Corporate insiders own 13.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of DERM. Point72 Asset Management L.P. increased its position in Dermira by 621.8% in the third quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after buying an additional 614,138 shares during the period. BlackRock Inc. increased its position in Dermira by 15.6% in the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after buying an additional 529,405 shares during the period. Voya Investment Management LLC increased its position in Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after buying an additional 467,356 shares during the period. Jennison Associates LLC increased its position in Dermira by 16.7% in the second quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock worth $76,725,000 after buying an additional 377,554 shares during the period. Finally, State Street Corp increased its position in Dermira by 38.4% in the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after buying an additional 228,093 shares during the period. 99.54% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Dermira (DERM) Now Covered by Analysts at Guggenheim” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/dermira-derm-earns-buy-rating-from-analysts-at-guggenheim.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.